Lamivudine therapy for hepatitis B infection

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• New antiviral agents show promise in inhibiting hepatitis B virus (HBV) replication.
• Lamivudine is a widely studied agent for chronic hepatitis B.
• Extensive clinical trials have been conducted for lamivudine in chronic hepatitis B patients.

Purpose of the Study:

• To evaluate the efficacy and safety of lamivudine in treating chronic hepatitis B.
• To assess the impact of lamivudine on viral replication, seroconversion, and liver histology.
• To determine the long-term outcomes and potential adverse events associated with lamivudine therapy.

Main Methods:

• Phase II and III clinical studies involving patients with chronic hepatitis B.
• Administration of 100 mg lamivudine daily.
• Monitoring of HBeAg seroconversion rates, HBV DNA levels, serum aminotransferases, and hepatic histology.
• Assessment of genotypic mutations and drug resistance.

Main Results:

• Sustained HBeAg seroconversion rates increased from 17% at year one to 27% after 2 years.
• Histological improvement observed in 38%-52% of lamivudine-treated patients, exceeding placebo.
• In anti-HBe positive, HBV DNA positive patients, 65% became HBV DNA negative after one year.
• Genotypic mutations leading to resistance were observed in 11% after 1 year, doubling after 2 years.

Conclusions:

• Lamivudine demonstrates significant efficacy in inhibiting HBV replication and improving liver health.
• Long-term lamivudine therapy is likely required to achieve substantial reduction in infected hepatocytes and prevent relapse.
• Lamivudine is generally well-tolerated but resistance can develop over time.
• The drug is indicated for patients with replicative hepatitis B infection, active chronic hepatitis, and/or cirrhosis.